Slingshot members are tracking this event:

Agios Pharma (AGIO) to complete Phase 1 study of AG-120 in subjects With Advanced Hematologic Malignancies With an IDH1 Mutation in September 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details An ongoing Phase 1 trial that includes a dose escalation phase and three expansion cohorts, including a homogenous population of 125 AML patients who relapsed after bone marrow transplantation, are in second or later relapse, refractory to second line induction or reinduction treatment. The study’s primary objectives are to confirm the safety and clinical activity of AG-120
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1 Study, Ag-120, Hematologic Malignancies, Acute Myeloid Leukemia, Idh1 Mutation, Open-label